Scholarlink

<p>Infarct-limiting efficacy of endomorphin‑1, a peptide agonist of μ<sub>2</sub>‑opioid receptors (μ<sub>2</sub>‑OR), was studied in rats with metabolic syndrome and during aging. Metabolic syndrome was induced by HFHC diet for 84 days. Coronary artery occlusion (45 min) and reperfusion (2 h) were modeled. Endomorphin‑1 produced a pronounced infarct-limiting effect in control 5‑month-old animals; however, this effect was significantly attenuated in aged (18‑month-old) rats and did not appear in 5‑month-old rats with metabolic syndrome. The μ<sub>2</sub>‑OR agonist endomorphin‑1 is a promising compound for cardioprotection, but its efficacy in the treatment of myocardial infarction in elderly patients and in metabolic syndrome requires additional studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Infarct-Limiting Efficacy of the μ2‑Opioid Receptor Peptide Agonist Endomorphin‑1 in Metabolic Syndrome and Aging

  • 期刊论文

  • 发表日期：

    2026年6月2日

查看全文
  • N. V. Naryzhnaya,
  • A. V. Mukhomedzyanov,
  • I. A. Derkachev,
  • B. K. Kurbatov,
  • M. Kilin,
  • A. Kan,
  • L. N. Maslov

摘要

Infarct-limiting efficacy of endomorphin‑1, a peptide agonist of μ2‑opioid receptors (μ2‑OR), was studied in rats with metabolic syndrome and during aging. Metabolic syndrome was induced by HFHC diet for 84 days. Coronary artery occlusion (45 min) and reperfusion (2 h) were modeled. Endomorphin‑1 produced a pronounced infarct-limiting effect in control 5‑month-old animals; however, this effect was significantly attenuated in aged (18‑month-old) rats and did not appear in 5‑month-old rats with metabolic syndrome. The μ2‑OR agonist endomorphin‑1 is a promising compound for cardioprotection, but its efficacy in the treatment of myocardial infarction in elderly patients and in metabolic syndrome requires additional studies.